Q-omics provides the consensus-scored MDS2 profile across patient tissues and cancer cell-line models. MDS2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MDS2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MDS2 RNA expression shows 12,538 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where MDS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MDS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MDS2 survival associations across molecular data types. MDS2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MDS2 RNA expression–survival associations across cancer types. High MDS2 expression shows unfavorable associations in COAD, KIRP and UVM, but favorable associations in SKCM, STAD and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MDS2 RNA expression.
This table summarizes MDS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MDS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MDS2 shows lower tumor expression in THCA, LUSC and LUAD and higher tumor expression in KIRC, HNSC and BRCA. The KIRC box plot shows higher MDS2 RNA expression in tumor versus normal tissue (log2 FC = +0.241, t-test p < 0.001).
This table shows molecular features associated with MDS2 in patient tissues and cancer cell lines. In patient samples, MDS2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MDS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and URINARY_TRACT.
